LC-2/AD 人肺癌腺癌细胞

建立从胸腔积液肺腺癌在51岁的日本女性。LC-2/ad细胞呈上皮状，倾向于形成小圆丘。免疫细胞化学染色显示CEA和细胞角蛋白阳性，包括细胞角蛋白No.18。LC-2/ad在体外产生至少两种功能活性胰蛋白酶抑制剂和几种蛋白酶经无支原体/STR鉴定入库。

动物种别/Organism 日本女性，51岁

组织来源 Tissue and Cell Type 胸腔积液，肺腺癌

形态/Morphology 上皮细胞样，贴壁生长

培养基和添加剂/Complete Growth Medium and Culture Conditions：

45%1640(MD0200)+45%F12(MD0500)+10%胎牛血清(SD0200)+SP（SD0008）+

G/A (SD0038)

气相：空气，95%；二氧化碳，5%。 温度：37摄氏度。

冻存条件：基础培养基+5%DMSO+20%FBS(SD0200)

完全冻存液：免程序降温细胞冻存液（低血清）(SD0001)

注意事项：此产品仅供科研使用

PubMed=8291444; DOI=10.1111/j.1440-1827.1993.tb03232.x

Kataoka H., Itoh H., Seguchi K., Koono M.

Establishment and characterization of a human lung adenocarcinoma cell line (LC-2/ad) producing alpha 1-antitrypsin in vitro.

Acta Pathol. Jpn. 43:566-573(1993)

PubMed=8348978; DOI=10.1016/0014-5793(93)80946-R

Kataoka H., Seguchi K., Inoue T., Koono M.

Properties of alpha 1-antitrypsin secreted by human adenocarcinoma cell lines.

FEBS Lett. 328:291-295(1993)

PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331

Nagai Y., Miyazawa H., Huqun X., Tanaka T., Udagawa K., Kato M., Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.

Cancer Res. 65:7276-7282(2005)

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=22313637; DOI=10.4161/cbt.19238

Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A., Igishi T., Burioka N., Nanba E., Shimizu E.

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.

Cancer Biol. Ther. 13:369-378(2012)

PubMed=23154560; DOI=10.1097/JTO.0b013e3182721ed1

Matsubara D., Kanai Y., Ishikawa S., Ohara S., Yoshimoto T., Sakatani T., Oguni S., Tamura T., Kataoka H., Endo S., Murakami Y., Aburatani H., Fukayama M., Niki T.

Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.

J. Thorac. Oncol. 7:1872-1876(2012)

PubMed=23578175; DOI=10.1111/cas.12175

Suzuki M., Makinoshima H., Matsumoto S., Suzuki A., Mimaki S., Matsushima K., Yoh K., Goto K., Suzuki Y., Ishii G., Ochiai A., Tsuta K., Shibata T., Kohno T., Esumi H., Tsuchihara K.

Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.

Cancer Sci. 104:896-903(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)